Evidence · Systematic review or meta-analysis
Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis.
- Growth
- Medical
- Metabolic, endocrine and renal
- Neurodevelopmental follow-up
- Nutrition and gastrointestinal
- Postnatal and transitional care
This paper is from 2019, more than five years ago. Newer evidence may have been published since.
Summary
Systematic review and meta-analysis of 28 randomised studies comparing maternal metformin versus insulin treatment for gestational diabetes, examining neonatal, infant and childhood growth outcomes. Neonates exposed to metformin had lower birth weight and less macrosomia than those exposed to insulin. Metformin-exposed children appeared to show accelerated postnatal growth, with heavier infants and higher BMI by mid-childhood. The authors highlight possible long-term cardio-metabolic implications and call for longitudinal follow-up studies.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.